biote Corp. (BTMD) Fair Value 2026

BTMD · Medical Care Facilities ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.7 /10

32 fundamental signals · 6 models active

Value Trap Risk

SAFE (20/100)

Quick Summary — As of 2026-08-28, biote Corp. (BTMD) trades at $1.57, versus a $3.58 median fair value across its 6 active models — 128.3% above the current price. QOC: 7.7/10. Value Trap Risk: 20/100 (SAFE). 6/13 models active. Within that set, the Bayesian DCF component alone returns $5.10.

Key Facts

Ticker
BTMD
Price
$1.57
Quality Score
7.7/10
Value Trap Risk
20/100
Models Active
6/13
Last Updated
Strength: CUCE Ensemble suggests +466.6% upside with 5% confidence
Risk: Limited model coverage (6/13) may reduce confidence

Is biote Corp. (BTMD) Undervalued or Overvalued in 2026?

According to CirclFi’s 6-model valuation engine, biote Corp. (BTMD) appears undervalued as of : the median of 6 independent fair value estimates is $3.58, 128.3% above the current price of $1.57. Estimates range from $0.32 to $9.19. BTMD scores 7.7/10 on fundamental quality and 20/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. BTMD’s +128.3% gap is wider than that market norm, and the Medical Care Facilities sector median is -28.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy biote Corp. Stock in 2026? →

What Fair Value Does Each Model Give BTMD?

6 Intrinsic Value Models vs. Current Price ($1.57)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $5.10 +225.1%
Intrinsic · High Conviction
 $0.32 -79.6%
Ensemble · Low Conviction
 $8.90 +466.6%
Unlock the Full Matrix

Access 3 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 6 Models →

Cancel anytime · No contracts · Instant access

What Is BTMD's Fair Value Range?

Spread across 6 independent models · $0.32 to $9.19

CirclFi's 6 active models place biote Corp. (BTMD) between $0.32 and $9.19 per share, a spread of 247% of the median. The median of that range — $3.58 — is the fair value CirclFi publishes for BTMD, against a current price of $1.57.

Low · EPVHigh · PWERM
$0.32median $3.58$9.19
Where the range comes from
Most bearish modelEarnings Power Value (EPV)$0.32
Most bullish modelPWERM$9.19
Model agreement4 bullish · 2 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BTMD. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BTMD, not a CirclFi price target. How each model works →

What Is biote Corp. (BTMD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, biote Corp.'s intrinsic value is estimated at a median fair value of $3.58. While the stock appears modestly undervalued at $1.57 (implied upside of +128.3%), our analysis suggests a thinner margin of safety across 4 of 6 bullish models. Notably, PWERM sees the most upside at +485.3% (fair value: $9.19), while EPV is the most conservative at -79.6% ($0.32). The spread between these extremes — +564.8% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About BTMD?

6 of 13 models are currently active for BTMD. Of these, 4 models suggest upside while 2 models suggest overvaluation. Taken together, their median fair value for BTMD is $3.58 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $5.10 on its own, implying +225.1% upside from the current price. See which stocks rank higher →

How Does BTMD Rank in Medical Care Facilities?

Among 60 Medical Care Facilities stocks, BTMD ranks #17 by Quality of Company score. CirclFi's QOC score of 7.7/10 evaluates 32 fundamental signals. A score of 7.7 indicates above-average quality.

See all Most Undervalued Medical Care Facilities Stocks →

biote Corp. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BTMD a Value Trap?

CirclFi's Value Trap algorithm assigns BTMD a score of 20/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

6 of 13 models are active for biote Corp.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, biote Corp. is rated at 7.7/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.

The gap between the most bullish and bearish model spans +564.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BTMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BTMD's 6 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy biote Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Care Facilities Stocks Should You Also Analyze?

10 related Medical Care Facilities stocks with 13-model coverage

HCSGHealthcare Services Group, Inc.QOC 7.7GRDNGuardian Pharmacy Services, Inc.QOC 7.6PACSPACS Group, Inc.QOC 7.8DVADaVita Inc.QOC 7.5MDPediatrix Medical Group, Inc.QOC 7.9CONConcentra Group Holdings Parent, Inc.QOC 7.5SRTAStrata Critical Medical, Inc.QOC 6.5WWWW International, Inc.QOC 5.5NHCNational HealthCare CorporationQOC 8.7ADUSAddus HomeCare CorporationQOC 8.9

Read investment analysis: HCSG · GRDN · PACS · DVA · MD · CON · SRTA · WW · NHC · ADUS

Which Other Stocks Have a Similar Quality Score to BTMD?

7 companies across all industries closest to BTMD’s Quality of Company score of 7.7/10.

HLIOHelios Technologies, Inc.QOC 7.7AESThe AES CorporationQOC 7.7HASIHA Sustainable Infrastructure Capital, Inc.QOC 7.7SAROStandardAero, Inc.QOC 7.7WYNNWynn Resorts, LimitedQOC 7.7MGMistras Group, Inc.QOC 7.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: HLIO · AES · HASI · SARO · WYNN · MG · NVDA

Where Does BTMD Sit in CirclFi's Medical Care Facilities Rankings?

BTMD is ranked against every other Medical Care Facilities stock CirclFi covers in each of these screens.

See all Medical Care Facilities stocks ranked →

What Else Do Investors Ask About biote Corp.’s Valuation?

What is biote Corp.'s intrinsic value in 2026?

CirclFi puts biote Corp. (BTMD)'s intrinsic value at $3.58 — the median of 6 independent model estimates as of 2026-08-28, ranging from $0.32 to $9.19. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $5.10 on its own. The Quality of Company score is 7.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BTMD overvalued or undervalued right now?

At $1.57, 4 of 6 active models suggest BTMD may be undervalued, while 2 indicate potential overvaluation. The median of all 6 fair value estimates is $3.58, 128.3% above the current price of $1.57 — a consensus view that BTMD is undervalued. The assessment depends on which methodology best fits biote Corp.'s business model in Medical Care Facilities.

What does a Quality of Company score of 7.7 mean for BTMD?

biote Corp.'s QOC of 7.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on BTMD?

CirclFi analyzes BTMD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 6 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BTMD?

Of the 6 models currently active on BTMD, PWERM is the most bullish at $9.19 per share, and Earnings Power Value (EPV) is the most bearish at $0.32. CirclFi's published fair value for BTMD is the median of that range, $3.58, not either extreme. The gap between the two ends equals 247% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BTMD a value trap in 2026?

biote Corp.'s Value Trap score is 20/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 6-model valuation engine, biote Corp. (BTMD) has a median fair value of $3.58 — 128.3% above the current price of $1.57 — as of 2026-08-28.” Source: circlfi.com/stock/BTMD/ · Methodology
Primary sources for this BTMD valuation
  • Financial statements: biote Corp. 10-K and 10-Q filings on SEC EDGAR (CIK 0001819253) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BTMD as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 6 mathematical frameworks give you clarity on BTMD.

Unlock All 6 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for BTMD Unlock All 6 — $39/mo